{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T18:23:38Z","timestamp":1794248618789,"version":"4.9.0"},"reference-count":61,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","license":[{"start":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T00:00:00Z","timestamp":1742515200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,3,21]]},"abstract":"<jats:p>\n                    Clinically, approximately 10% to 20% of small cell lung cancer (SCLC) patients do not respond well to initial platinum-based first-line chemotherapy. Knowledge about the clinicopathologic characteristics of these primary drug-resistant populations is limited. This study aimed to explore the clinicopathologic characteristics in SCLC populations insensitive to initial chemotherapy. This study enrolled SCLC patients with insensitivity to initial chemotherapy and analyzed their clinicopathological characteristics. Binary logistic regression analysis was used to determine the independent factors that influence chemosensitivity. The study evaluated 142 cases to determine the clinicopathologic characteristics of SCLC populations with insensitivity to initial chemotherapy. Between the chemotherapy-insensitive group (n\u2005=\u200532) and the chemotherapy-sensitive group (n\u2005=\u2005110), no significant differences were observed in sex, age, smoking status, tumor size, lymph-node metastasis, vascular invasion, carcinomatous lymphangitis, mediastinal invasion, superior vena cava syndrome, tumor stage, brain metastases, pleural metastasis, lung metastasis, adrenal metastasis, or the immunohistochemical markers cytokeratin, synaptophysin, chromogranin A, thyroid transcription factor-1, and Ki-67 (all\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&gt;\u2005.05). However, significant differences in liver metastasis (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.005), bone metastasis (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.001), and neural cell adhesion molecule expression (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.027) were identified. Binary logistic regression analysis revealed that bone metastasis (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.008) was an independent high-risk factor for insensitivity to initial first-line chemotherapy. Bone metastasis is an independent high-risk factor for insensitivity to initial chemotherapy in SCLC. Enhancing our understanding of SCLC biology and osteoimmuno-oncology could identify new vulnerabilities and better define patient populations that may benefit from tailored clinical treatments to overcome drug resistance.\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000041953","type":"journal-article","created":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T03:14:57Z","timestamp":1743045297000},"page":"e41953","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Exploring resistance to initial chemotherapy in small cell lung cancer: The role of bone metastasis and other clinicopathologic characteristics"],"prefix":"10.1097","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9675-4461","authenticated-orcid":false,"given":"Yulong","family":"He","sequence":"first","affiliation":[{"name":"Department of Oncology, Nanxishan Hospital of the Guangxi Zhuang Autonomous Region, Guilin, Guangxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaorong","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Spine Surgery, Guilin People\u2019s Hospital, Guilin, Guangxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Nanxishan Hospital of the Guangxi Zhuang Autonomous Region, Guilin, Guangxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinling","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Nanxishan Hospital of the Guangxi Zhuang Autonomous Region, Guilin, Guangxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Deng","sequence":"additional","affiliation":[{"name":"Department of Oncology, Nanxishan Hospital of the Guangxi Zhuang Autonomous Region, Guilin, Guangxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenwang","family":"Lang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Nanxishan Hospital of the Guangxi Zhuang Autonomous Region, Guilin, Guangxi, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20261109","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.semcancer.2022.11.006","article-title":"The role of stem cells in small-cell lung cancer: evidence from chemoresistance to immunotherapy.","volume":"87","author":"Guo","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"R2-20261109","first-page":"7","article-title":"Cancer statistics.","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"R3-20261109","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1158\/1078-0432.CCR-20-2845","article-title":"AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, shows high potency and sensitivity in preclinical models of small-cell lung cancer.","volume":"27","author":"Giffin","year":"2021","journal-title":"Clin Cancer Res"},{"key":"R4-20261109","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13045-023-01464-y","article-title":"Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer.","volume":"16","author":"Rudin","year":"2023","journal-title":"J Hematol Oncol"},{"key":"R5-20261109","doi-asserted-by":"crossref","first-page":"8129","DOI":"10.3390\/ijms24098129","article-title":"Small-cell lung cancer-An update on targeted and immunotherapies.","volume":"24","author":"McNamee","year":"2023","journal-title":"Int J Mol Sci"},{"key":"R6-20261109","doi-asserted-by":"crossref","first-page":"6289","DOI":"10.3390\/curroncol30070465","article-title":"Canadian consensus recommendations on the management of extensive-stage small-cell lung cancer.","volume":"30","author":"Melosky","year":"2023","journal-title":"Curr Oncol"},{"key":"R7-20261109","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.annonc.2021.03.207","article-title":"Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.","volume":"32","author":"Dingemans","year":"2021","journal-title":"Ann Oncol"},{"key":"R8-20261109","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1200\/JCO.2011.40.4905","article-title":"Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data.","volume":"30","author":"Rossi","year":"2012","journal-title":"J Clin Oncol"},{"key":"R9-20261109","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1158\/1078-0432.CCR-17-1932","article-title":"Mechanistic exploration of cancer stem cell marker voltage-dependent calcium channel \u03b12\u03b41 subunit-mediated chemotherapy resistance in small-cell lung cancer.","volume":"24","author":"Yu","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"Pt 3","key":"R10-20261109","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.semcancer.2022.02.021","article-title":"Evolving role of immunotherapy in small cell lung cancer.","volume":"86","author":"Barrows","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"R11-20261109","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1080\/14712598.2019.1592155","article-title":"Immunotherapy for small cell lung cancer: mechanisms of resistance.","volume":"19","author":"Hamilton","year":"2019","journal-title":"Expert Opin Biol Ther"},{"issue":"Pt 3","key":"R12-20261109","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.semcancer.2022.03.009","article-title":"Ferroptosis, necroptosis, and pyroptosis in the tumor microenvironment: Perspectives for immunotherapy of SCLC.","volume":"86","author":"Niu","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"R13-20261109","first-page":"547","article-title":"Analysis of correlation between TTF-1 and sensitivity to first-line chemotherapy and prognosis in patients with small cell lung cancer.","volume":"23","author":"Wang","year":"2020","journal-title":"Zhongguo Fei Ai Za Zhi"},{"key":"R14-20261109","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1097\/JTO.0000000000000630","article-title":"The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification.","volume":"10","author":"Travis","year":"2015","journal-title":"J Thorac Oncol"},{"key":"R15-20261109","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"R16-20261109","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/1759-7714.14785","article-title":"Challenges of the eighth edition of the American Joint Committee on Cancer staging system for pathologists focusing on early stage lung adenocarcinoma.","volume":"14","author":"Wang","year":"2023","journal-title":"Thorac Cancer"},{"key":"R17-20261109","first-page":"989","article-title":"Chinese expert consensus on lung and thymus neuroendocrine neoplasms.","volume":"43","year":"2021","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"R18-20261109","first-page":"522","article-title":"Prognostic and predictive value of thyroid transcription factor-1, CD56, P40 and other clinical characteristics in small cell lung cancer patients.","volume":"20","author":"Wang","year":"2017","journal-title":"Zhongguo Fei Ai Za Zhi"},{"key":"R19-20261109","first-page":"948","article-title":"Understanding SCLC heterogeneity and plasticity in cancer metastasis and chemotherapy resistance.","volume":"55","author":"Jin","year":"2023","journal-title":"Acta Biochim Biophys Sin (Shanghai)"},{"key":"R20-20261109","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/jso.25960","article-title":"Insulinoma-associated protein 1 is a prognostic biomarker in pulmon-ary high-grade neuroendocrine carcinoma.","volume":"122","author":"Minami","year":"2020","journal-title":"J Surg Oncol"},{"key":"R21-20261109","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1007\/s00432-022-03970-x","article-title":"Pulmonary neuroendocrine tumors:study of 266 cases focusing on clinicopathological characteristics, immunophenotype, and prognosis.","volume":"149","author":"Zhang","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"R22-20261109","first-page":"15","article-title":"Proliferation marker (Ki67) in sub-categorization of neuroendocrine tumours of the lung.","volume":"35","author":"Garg","year":"2019","journal-title":"Turk Patoloji Derg"},{"key":"R23-20261109","doi-asserted-by":"crossref","first-page":"e031531","DOI":"10.1136\/bmjopen-2019-031531","article-title":"The utility of Ki-67 as a prognostic biomarker in pulmonary neuroendocrine tumours: protocol for a systematic review and meta-analysis.","volume":"9","author":"Naheed","year":"2019","journal-title":"BMJ Open"},{"key":"R24-20261109","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.21037\/jtd-21-216","article-title":"Curative efficacy might be an early predictor of prognosis in patients with small cell lung cancer treated with 2 cycles of platinum-based first-line chemotherapy.","volume":"13","author":"Zhu","year":"2021","journal-title":"J Thorac Dis"},{"key":"R25-20261109","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13000-015-0250-z","article-title":"Value of thyroid transcription factor (TTF)-1 for diagnosis and prognosis of patients with locally advanced or metastatic small cell lung cancer.","volume":"10","author":"Misch","year":"2015","journal-title":"Diagn Pathol"},{"key":"R26-20261109","doi-asserted-by":"crossref","first-page":"e73215","DOI":"10.1371\/journal.pone.0073215","article-title":"Differences in chemosensitivity between primary and metastatic tumors in colorectal cancer.","volume":"8","author":"Takebayashi","year":"2013","journal-title":"PLoS One"},{"key":"R27-20261109","doi-asserted-by":"crossref","first-page":"45351","DOI":"10.1038\/srep45351","article-title":"TTF-1- and\/or CD56-positive Circulating Tumor Cells in patients with small cell lung cancer (SCLC).","volume":"7","author":"Messaritakis","year":"2017","journal-title":"Sci Rep"},{"key":"R28-20261109","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.ccell.2024.01.010","article-title":"Immune heterogeneity in small-cell lung cancer and vulnerability to immune checkpoint blockade.","volume":"42","author":"Nabet","year":"2024","journal-title":"Cancer Cell"},{"key":"R29-20261109","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1016\/j.ccell.2021.09.008","article-title":"Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer.","volume":"39","author":"Chan","year":"2021","journal-title":"Cancer Cell"},{"key":"R30-20261109","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1158\/2159-8290.CD-20-0913","article-title":"Intrinsic immunogenicity of small cell lung carcinoma revealed by its cellular plasticity.","volume":"11","author":"Mahadevan","year":"2021","journal-title":"Cancer Discov"},{"key":"R31-20261109","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.semcancer.2022.11.005","article-title":"Emerging role of chemokines in small cell lung cancer: Road signs for metastasis, heterogeneity, and immune response.","volume":"87","author":"Khan","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"R32-20261109","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ccell.2020.05.001","article-title":"MYC drives temporal evolution of small cell lung cancer subtypes by Reprogramming Neuroendocrine Fate.","volume":"38","author":"Ireland","year":"2020","journal-title":"Cancer Cell"},{"key":"R33-20261109","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41568-019-0133-9","article-title":"Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data.","volume":"19","author":"Rudin","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"R34-20261109","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1038\/s41467-021-22336-4","article-title":"Ferroptosis response segregates small cell lung cancer (SCLC) neuroendocrine subtypes.","volume":"12","author":"Bebber","year":"2021","journal-title":"Nat Commun"},{"key":"R35-20261109","doi-asserted-by":"crossref","first-page":"302ra136","DOI":"10.1126\/scitranslmed.aac9459","article-title":"A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo.","volume":"7","author":"Saunders","year":"2015","journal-title":"Sci Transl Med"},{"key":"R36-20261109","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/nrclinonc.2017.71","article-title":"Unravelling the biology of SCLC: implications for therapy.","volume":"14","author":"Sabari","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"R37-20261109","doi-asserted-by":"crossref","first-page":"6958","DOI":"10.1158\/1078-0432.CCR-19-1133","article-title":"Efficacy and safety of rovalpituzumab tesirine in third-line and beyond patients with DLL3-expressing, relapsed\/refracttory small-cell lung cancer: results from the phase II TRINITY study.","volume":"25","author":"Morgensztern","year":"2019","journal-title":"Clin Cancer Res"},{"key":"R38-20261109","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13045-019-0745-2","article-title":"DLL3: an emerging target in small cell lung cancer.","volume":"12","author":"Owen","year":"2019","journal-title":"J Hematol Oncol"},{"key":"R39-20261109","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1080\/14728222.2020.1723548","article-title":"MYC, MYCL, and MYCN as therapeutic targets in lung cancer.","volume":"24","author":"Masso-Valles","year":"2020","journal-title":"Expert Opin Therapeutic Targets"},{"key":"R40-20261109","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.omto.2021.02.004","article-title":"Molecular profiles of small cell lung cancer subtypes: therapeutic implications.","volume":"20","author":"Schwendenwein","year":"2021","journal-title":"Mol Ther Oncolytics"},{"key":"R41-20261109","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1038\/s41467-019-11371-x","article-title":"MYC paralog-dependent apoptotic priming orchestrates a spectrum of vulnerabilities in small cell lung cancer.","volume":"10","author":"Dammert","year":"2019","journal-title":"Nat Commun"},{"key":"R42-20261109","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jtho.2019.10.013","article-title":"Randomized phase II study of paclitaxel plus alisertib versus paclitaxel plus placebo as second-line therapy for SCLC: primary and correlative biomarker analyses. J Thoracic Oncol.","volume":"15","author":"Owonikoko","year":"2020","journal-title":"J Thor Oncol"},{"key":"R43-20261109","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.jtho.2020.11.006","article-title":"YAP1 expression in SCLC defines a distinct subtype with T-cell-Inflamed phenotype.","volume":"16","author":"Owonikoko","year":"2021","journal-title":"J Thoracic Oncol"},{"key":"R44-20261109","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/s41419-020-2379-2","article-title":"MCL1 inhibition is effective against a subset of small cell lung cancer with high MCL1 and low BCL-XL expression.","volume":"11","author":"Yasuda","year":"2020","journal-title":"Cell Death Dis"},{"key":"R45-20261109","doi-asserted-by":"crossref","first-page":"e620","DOI":"10.1002\/ctm2.620","article-title":"Integrative analysis of multi-omics data reveals the heterogeneity and signatures of immune therapy for small cell lung cancer.","volume":"11","author":"Chen","year":"2021","journal-title":"Clin Transl Med"},{"issue":"Pt 2","key":"R46-20261109","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.semcancer.2022.07.008","article-title":"Novel therapeutic combinations with PARP inhibitors for small cell lung cancer: a bench-to-bedside review.","volume":"86","author":"Xiong","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"R47-20261109","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1158\/2159-8290.CD-12-0112","article-title":"Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP-1.","volume":"2","author":"Byers","year":"2012","journal-title":"Cancer Discov"},{"key":"R48-20261109","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1158\/1078-0432.CCR-11-2059","article-title":"Phase II trial of temozolomide in patients with relapsed sensitive or refractory small cell lung cancer, with assessment of methylguanine-DNA methyltransferase as a potential biomarker.","volume":"18","author":"Pietanza","year":"2018","journal-title":"Clin Cancer Res"},{"key":"R49-20261109","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1200\/JCO.2018.77.7672","article-title":"Randomized, double-blind, phase II study of temo-zolomide in combination with either veliparib or placebo in patients with relapsed-sensitive or refractory small-cell lung cancer.","volume":"36","author":"Pietanza","year":"2018","journal-title":"J Clin Oncol"},{"key":"R50-20261109","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1158\/2159-8290.CD-19-0582","article-title":"Combination olaparib and temozolomide in relapsed small-cell lung cancer.","volume":"9","author":"Farago","year":"2019","journal-title":"Cancer Discov"},{"key":"R51-20261109","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/annonc\/mdz192","article-title":"A decade of clinical development of PARP inhibitors in perspective.","volume":"30","author":"Mateo","year":"2019","journal-title":"Ann Oncol"},{"key":"R52-20261109","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/s41565-023-01374-7","article-title":"Neutrophil hitchhiking for drug delivery to the bone marrow.","volume":"18","author":"Luo","year":"2023","journal-title":"Nat Nanotechnol"},{"key":"R53-20261109","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.3390\/cells10061529","article-title":"Osteoimmuno-oncology: therapeutic opportunities for targeting immune cells in bone metastasis.","volume":"10","author":"K\u00e4hk\u00f6nen","year":"2021","journal-title":"Cells"},{"key":"R54-20261109","doi-asserted-by":"crossref","first-page":"1121878","DOI":"10.3389\/fimmu.2023.1121878","article-title":"Insights into immuno-oncology drug development landscape with focus on bone metastasis.","volume":"14","author":"K\u00e4hk\u00f6nen","year":"2023","journal-title":"Front Immunol"},{"key":"R55-20261109","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s00296-020-04665-7","article-title":"Immune checkpoint inhibitor-induced musculoskeletal manifestations.","volume":"41","author":"Angelopoulou","year":"2021","journal-title":"Rheumatol Int"},{"key":"R56-20261109","doi-asserted-by":"crossref","first-page":"8970173","DOI":"10.1155\/2021\/8970173","article-title":"Immune checkpoint inhibitor therapy for bone metastases: specific microenvironment and current situation.","volume":"2021","author":"Liu","year":"2021","journal-title":"J Immunol Res"},{"key":"R57-20261109","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S1470-2045(19)30689-8","article-title":"Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial.","volume":"21","author":"Schmid","year":"2020","journal-title":"Lancet Oncol"},{"key":"R58-20261109","doi-asserted-by":"crossref","first-page":"9067","DOI":"10.1200\/JCO.2022.40.16_suppl.9067","article-title":"Treatment with or without chemotherapy in high-risk, stage IVA\/B NSCLC.","volume":"40","author":"Leitzel","year":"2022","journal-title":"J Clin Oncol"},{"key":"R59-20261109","first-page":"1797","article-title":"Translational research of PT-112, a clinical agent in advanceed phase I development: evident bone tropism, synergy In vitro with bortezomib and lenalidomide, and potent efficacy in the Vk*MYC mouse model of multiple myeloma.","volume":"130","author":"Ames","year":"2017","journal-title":"Blood"},{"key":"R60-20261109","doi-asserted-by":"crossref","first-page":"17025","DOI":"10.1200\/JCO.2021.39.15_suppl.e17025","article-title":"A phase 1b study of novel immunogenic cell death inducer PT-112 plus PD-L1 inhibitor avelumab in metastatic castrate resistant prostate cancer (mCRPC) patients.","volume":"39","author":"Bryce","year":"2021","journal-title":"J Clin Oncol"},{"key":"R61-20261109","doi-asserted-by":"crossref","first-page":"101430","DOI":"10.1016\/j.eclinm.2022.101430","article-title":"Phase I study of PT-112, a novel pyrophosphate-platinum immunogenic cell death inducer, in advanced solid tumours.","volume":"49","author":"Karp","year":"2022","journal-title":"EClinical Medicine"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000041953","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T18:01:18Z","timestamp":1794247278000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000041953"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,21]]},"references-count":61,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000041953","relation":{},"ISSN":["1536-5964","0025-7974"],"issn-type":[{"value":"1536-5964","type":"electronic"},{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3,21]]}}}